RxDoctor Payments Data

Cecil George, MD

Internal Medicine · Greenbelt, MDNPI 1245311000

Payments from drug & device makers

$503in general payments, 2019–2025

Across 23 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$121
  • Novartis$101
  • Medtronic$85
  • Amgen$75
  • AbbVie$56
  • GSK$19
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$503100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$503 in reported general payments places this provider in the 65th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$177,715
Medicare patients
385
Services billed
2,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide79$118,776
EliquisApixaban62$84,821
JardianceEmpagliflozin55$82,970
TrulicityDulaglutide27$42,216
OzempicSemaglutide38$40,616
JanumetSitagliptin Phos/Metformin Hcl28$36,296
JanuviaSitagliptin Phosphate51$35,772
LinzessLinaclotide20$32,155
XareltoRivaroxaban21$15,275
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,572
Tresiba Flextouch U-100Insulin Degludec16$12,187
Janumet XrSitagliptin Phos/Metformin Hcl13$10,927
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$10,033
DuleraMometasone/Formoterol15$4,961
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$4,756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$84,82162 claims
Novo NordiskOzempic$13$40,61638 claims
AbbVieLinzess, Synthroid$56$33,82853 claims
GSKTrelegy Ellipta, Anoro Ellipta$19$23,60530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Greenbelt

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →